Crossmark

Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial

Crossref DOI link: https://doi.org/10.1136/jitc-2021-003190

Published Online: 2022-01-06

Published Print: 2022-01

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Rob, Lukas

Cibula, David https://orcid.org/0000-0001-6387-9356
Knapp, Pawel

Mallmann, Peter

Klat, Jaroslav

Minar, Lubos

Bartos, Pavel

Chovanec, Josef

Valha, Petr

Pluta, Marek

Novotny, Zdenek

Spacek, Jiri

Melichar, Bohuslav

Kieszko, Dariusz

Fucikova, Jitka https://orcid.org/0000-0002-8423-479X
Hrnciarova, Tereza

Korolkiewicz, Roman Pawel https://orcid.org/0000-0002-9188-0327
Hraska, Marek

Bartunkova, Jirina

Spisek, Radek
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02107937 at ClinicalTrials.gov

Documents that mention this clinical trial

Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
https://doi.org/10.1136/jitc-2021-003190
Funding

Funding for this research was provided by:

SOTIO a.s.
License Information

License valid from 2022-01-05

Document is current

Any future updates will be listed below